Search results
Results from the WOW.Com Content Network
Product labeling for diagnostic 131 I iobenguane recommends giving potassium iodide one day before injection and continuing 5 to 7 days following. [ 19 ] 131 I iobenguane used for therapeutic purposes requires a different pre-medication duration, beginning 24–48 hours before iobenguane injection and continuing 10–15 days after injection.
Radioactive iodine (iodine-131) alone can potentially worsen thyrotoxicosis in the first few days after treatment. One side effect of treatment is an initial period of a few days of increased hyperthyroid symptoms. This occurs because when the radioactive iodine destroys the thyroid cells, they can release thyroid hormone into the blood stream.
Iodine-131 (usually as iodide) is a component of nuclear fallout, and is particularly dangerous owing to the thyroid gland's propensity to concentrate ingested iodine and retain it for periods longer than this isotope's radiological half-life of eight days. For this reason, people at risk of exposure to environmental radioactive iodine (iodine ...
This article lists veterinary pharmaceutical drugs alphabetically by name. Many veterinary drugs have more than one name and, therefore, the same drug may be listed more than once. Abbreviations are used in the list as follows: INN = International Nonproprietary Name; BAN = British Approved Name; USAN = United States Adopted Name
1. Ketogenic Diet. Cancer cells rely on glucose for energy to grow. The ketogenic diet is a way to provide an alternative energy source to normal cells in the dog's body while starving the cancer ...
Absorption half-life 1 h, elimination half-life 12 h. Biological half-life (elimination half-life, pharmacological half-life) is the time taken for concentration of a biological substance (such as a medication) to decrease from its maximum concentration (C max) to half of C max in the blood plasma.
Another well-known radioactive isotope used in medicine is Iodine-131, which is used as a radioactive label for some radiopharmaceutical therapies or the treatment of some types of thyroid cancer. [2]
131 I is a beta and gamma emitter. It is used both to destroy thyroid and thyroid cancer tissues (via beta radiation, which is short-range), and also other neuroendocrine tissues when used in MIBG. It can also be seen by a gamma camera, and can serve as a diagnostic imaging tracer, when treatment is also being attempted at the same time.